A 55-year-old type 2 diabetic patient with an eGFR of 25 mL/min/1.73m2 (CKD stage 4) requires initiation of GLP-1 receptor agonist therapy. Which agent is MOST appropriate given his renal function?
- A Semaglutide (oral) — it undergoes no renal elimination and is safe in severe CKD
- B Liraglutide — it is protein-bound and metabolized like endogenous glucagon-like peptides, not renally eliminated ✓
- C Exenatide — it is the most widely studied GLP-1RA in advanced CKD
- D Exenatide extended-release — depot formulation reduces peak levels and renal risk
Explanation
Exenatide (both immediate-release and extended-release) is primarily eliminated by the kidneys (glomerular filtration and proteolytic degradation), and is contraindicated or requires dose adjustment when eGFR <30 mL/min; it is not recommended in severe CKD. Liraglutide, semaglutide, and dulaglutide are metabolized proteolytically like endogenous proteins and are not primarily renally eliminated. Liraglutide has the most accumulated evidence for safety in moderate-to-severe CKD among injectable GLP-1RAs. Oral semaglutide uses SNAC (salcaprozate sodium) for absorption; while systemic elimination is non-renal, GI side effects may be more problematic. Liraglutide is generally preferred for eGFR 15-29 with clinical monitoring.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.